2) However residual value is defined, be it milestones or CVR's or licensing, it will help the share price.
I don't think these new guys are so smart ....that they want to silence Dr Jedd Wolchok and MSK and NCCN trials etc
We still have not heard about the 19 patients of 22 for Yervoy + Bavituximab
Safety profile is #1 and Biomarkers are the path to maximum shareholder value
Residual value does not have to mean breadcrumbed which is why it was an interesting choice of a word to use to describe the value of the pipeline
If PS Targeting is proven safety, no off target toxicities, increased responders.....etc ALL VIA BIOMARKERS and combines well with all SOC then the residual value would take on a different meaning, vs the typical depreciation where the residual value is the estimated scrap or salvage value at the end of the asset's useful life.
We are not at the end of the useful life of PS Targeting patents.....we are just beginning and Renegade Roger Lias seems afraid to say so
Sure seems like they are just puppets in the middle of an act where promises are made and maybe Roger realizes that he is the CEO and would be held 100% responsible
Listen carefully to NobleCon14 when Roger deflects in a way what is going on.....when he says ".. the decision had been made " but who made the decision lol
Everything signed off on while Roger is in place CEO he is still....the CEO with Fiduciary Duties and find himself in a Peregrine peculiar situation
Market Data 
Markets 
AI
